Announced Wed, 28 Jan, 2026 · 15:21 IST
Granules India Q3 FY26: Revenue up 22%, EBITDA up 34%, Peptide unit to break even in Q4
Mgmt Guided Margin ImprovementOrder Pipeline DisclosedInvestor Communications View source PDFExplain this filing
GRANULES · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Price reaction · full curve 14 horizons · vs prior close
-0.7%1-day move
₹578.55
prior close
₹565.00
base price
In-mkt
timing
5m10m15m30m1D2D3D4D5D7D15D1M2M3M
-0.0———-0.7-1.1-4.4-1.3+0.9-2.1+0.6-1.2+7.2+21.5
Up moveDown movePending
AI summary
Granules India Q3 FY26: revenue INR1,388 crores, up 22% YoY. EBITDA at INR308 crores, up 34% YoY, margin 22.2% (up 196 bps). Peptide unit Ascelis posted INR248 crores EBITDA loss but management expects Q4 FY26 breakeven. Gagillapur facility had post-warning letter meeting with FDA in January, submitting more documentation. ROCE rose to 16.8%. Preferential issue approved by shareholders for balance sheet strength.
Likely market impact
Strong quarter with margin expansion. Peptide breakeven in Q4 and Gagillapur FDA resolution are key near-term catalysts to watch.